Review of the application of RNA interference technology in the pharmaceutical industry.
Toxicol Pathol
; 35(3): 327-36, 2007 Apr.
Article
em En
| MEDLINE
| ID: mdl-17455080
ABSTRACT
Ribonucleic acid (RNA) interference (RNAi) is a recently discovered phenomenon whereby the introduction of double stranded (ds) RNA into the cytoplasm of the cell results in the specific and efficient degradation of complementary messenger (m) RNA and, therefore, reduced protein production. It was discovered by chance during attempts to develop flowers with increased colour intensity. The specific nature of the inhibition of protein production of cells has resulted in an explosion of research to understand and exploit RNAi. The technique is now established in in vitro systems, and much work is focussed in adapting RNAi for in vivo application. The potential of the technology in understanding physiological and pathological processes is significant, while its development as a therapeutic agent holds much promise as targeted agents. This review will describe the basic biological processes that drive RNAi, indicate current areas of areas research, and forecast future areas of development.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tecnologia
/
Interferência de RNA
/
Indústria Farmacêutica
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Toxicol Pathol
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Reino Unido